Shrooq Saleem Hussein 1 and Maha K. Almallak2,*
1Department of Biology, University of Basrah, College of Education for Pure Sciences, Basrah, Iraq
2Department of Biology, University of Basra, College of Science, Basrah, Iraq
*Corresponding Author: shrooqsaleem@stu.edu.iq
Received 1 March. 2025, Accepted 13 Dec. 2025, published 30 Dec. 2025.
AbstractKey wordsDOI
Objective: Cardiovascular disease (CVD) remains a leading cause of death and disability worldwide. This study investigated the therapeutic and preventive effects of losartan on myocardial infarction in male albino rats.
Methods: Cardiac infarction was induced in 100 rats using subcutaneous isoproterenol (65 mg/kg/day) for five days. Rats were divided into two main groups: Group 1 received isoproterenol only, while Group 2 was subdivided into four subgroups, including a losartan-pretreated group (losartan for 55 days prior to isoproterenol). Biochemical markers, including troponin, CK-MB, angiotensin II, glutathione (GSH), and total protein, were measured.
Results: Isoproterenol significantly increased troponin, CK-MB, and angiotensin II (p 0.001) and decreased GSH and total protein compared to controls. Losartan treatment restored GSH and total protein levels close to normal and significantly reduced cardiac injury markers (p 0.001).
Conclusion: Losartan demonstrates both protective and therapeutic effects against myocardial infarction, improving biochemical markers and suggesting potential clinical relevance.
cardiovascular diseases, heart infraction, losartan, Isoproterenol
Download full article